Doosan Babcock to build new GlaxoSmithKline plant in Montrose
Doosan Babcock has won a £25m contract to build a new pharmaceutical plant in Angus.
The UK engineering firm will work with GlaxoSmithKline (GSK) on an Active Pharmaceutical Ingredients facility in Montrose.
The plant will produce ingredients for new medicines for respiratory conditions such as asthma.
GSK's existing Montrose operations cater for more than 20 million patients a day.
It plans to recruit a further 25 employees at the facility once it is completed in summer 2016.
GSK first announced that it would expand its Montrose site in November 2013.
Doosan chief executive Andrew Hunt said: "This is a milestone contract for Doosan Babcock and it is great to see that our major investment and ongoing work in Scotland's pharmaceutical sector is being noticed.
"We are proud to be working with GSK on a project that will offer a major boost to the local economy, bring jobs to the region, and ultimately provide essential healthcare products for millions of people."
Last July, Doosan Babcock announced it would create 266 jobs at a new process engineering centre in Renfrewshire.
The firm, which provides services to the energy and pharmaceutical sectors, said it was investing £4.5m in the Renfrew facility, backed by Regional Selective Assistance from Scottish Enterprise.